S

INGAPORE — A young immuno-oncology company aims to pitch biomarker data for its lead drug candidate at the American Society of Clinical Oncology meeting in Chicago this summer, spreading the word about its ongoing Phase 3 trials.

Tessa Therapeutics could also send a message to fledgling Asian biotech hubs hoping to replicate the success of centers in other parts of the world.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories